Above the Clouds

VI International Summit

Heart Failure and Pulmonary Hypertension Management in the Polypharmacy and Device Era 

Heart Failure Review 2021

Liotta Symposium

November 29 - December 04, 2021

logo-VI-eng.png
70e8baa1-3579-4057-9798-419e57fcb0f8_edi
Perrone%25252C%252520Sergio_edited_edite
Mapa Asistencia Simposio 2020.png

Alejandro Barbagelata, MD, FAHA, FSCAI, FICA, MSAC
Program Director

Dr. Barbagelata is an invasive cardiologist with Heart Failure longstanding expertise. He was past director of the Heart failure, assist devices and Transplant at University of Texas medical branch. Professor of Medicine/Cardiology Duke University School of Medicine and Board of Directors of DUCCS (Duke University Cardiovascular Society). Member of the International Speaker Bureau of the American Heart Association. He Co-direct the Heart Failure program at the Catholic University and has privileges in several centers in private practice.

JOHN MC MURRAY

New Trials in Heart Failure.Where are we at the end of 2020

DAVID BARAN

Cardiogenic Shock

Sergio V. Perrone, MD, MTFACC, MTSACD
Program Director


Dr. Perrone was instrumental in generating the largest Heart Failure and Transplant program in South America in the early 80s and is an opinion leader in the region. He co-direct the heart failure program at the Catholic University and direct the Heart Failure and Pulmonary Hypertension Journal. He is the advisor in Heart Failure in a lot of Institutes in Argentina and in other South American Countries

JOHN CLELAND

Iron Deficiency in Heart Failure

 

MILTON PACKER

Quadruple Therapy as the new standard of care in heart failure with reduced EF

thumbnail_JMcM photoc ESC1.jpg
thumbnail_Baran_David_MD_SCS_5x7_edited.
66a90d91-6142-4ba4-83c6-f6de7a80129e.jpg
Milton.Packer.Radcliffe.jpeg

 JOSEPH ROGERS

VAD-Destination Therapy or Bridge?

 

BUD FRAZIER

Ventricular Assist Devices. Present and future

thumbnail_Frazier smiling-2.jpg
Chiefs.Rogers.03_PREFERRED.jpg

PILAR ESCRIBANO

pre and post capillary pulmonary hypertension. upfront therapy?

 

STEFAN ANKER 

Drug and devices in the treatment of hfpef. new options

Pilar Escribano
Stefan_D._Anker.png

ROBERT MENTZ

With arnis and sglt2, how can we manage polipharmacy in hf?

MARCELO DI CARLI

How imaging change the treatment paradigm in cardiomyopathies

Richard krasuski

support in pulmonary hypertension in advanced right heart failure

 Carlos morillo 

End stage hf patients keep need to keep or remove CRT-d? 

thumbnail_dcri_dscf1453.jpg
Dicarli, Marcelo.jpeg
Richard A. Krasuski
thumbnail_CMorillo%20closed_edited.jpg
Contact us

Thanks for submitting!

Shelley Zieroth, MD

Past President Canadian Heart Failure Society

Shelley Zieroth.jpeg
Lic. Sofia Barbagelata

Cordinatora Academica

Lic. Sofia Barbagelata